Terns Pharmaceuticals Statistics
Total Valuation
TERN has a market cap or net worth of $6.11 billion. The enterprise value is $5.09 billion.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TERN has 115.46 million shares outstanding. The number of shares has increased by 17.18% in one year.
| Current Share Class | 115.46M |
| Shares Outstanding | 115.46M |
| Shares Change (YoY) | +17.18% |
| Shares Change (QoQ) | +6.77% |
| Owned by Insiders (%) | 0.25% |
| Owned by Institutions (%) | 105.75% |
| Float | 115.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.91 |
| P/TBV Ratio | 6.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 62.41, with a Debt / Equity ratio of 0.00.
| Current Ratio | 62.41 |
| Quick Ratio | 62.09 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -14.23% and return on invested capital (ROIC) is -10.16%.
| Return on Equity (ROE) | -14.23% |
| Return on Assets (ROA) | -9.91% |
| Return on Invested Capital (ROIC) | -10.16% |
| Return on Capital Employed (ROCE) | -10.92% |
| Weighted Average Cost of Capital (WACC) | 2.18% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.63M |
| Employee Count | 59 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TERN has paid $581,000 in taxes.
| Income Tax | 581,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1,713.01% in the last 52 weeks. The beta is -0.38, so TERN's price volatility has been lower than the market average.
| Beta (5Y) | -0.38 |
| 52-Week Price Change | +1,713.01% |
| 50-Day Moving Average | 48.13 |
| 200-Day Moving Average | 26.80 |
| Relative Strength Index (RSI) | 74.10 |
| Average Volume (20 Days) | 7,451,764 |
Short Selling Information
The latest short interest is 8.06 million, so 6.98% of the outstanding shares have been sold short.
| Short Interest | 8.06M |
| Short Previous Month | 13.51M |
| Short % of Shares Out | 6.98% |
| Short % of Float | 7.00% |
| Short Ratio (days to cover) | 0.70 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -110.12M |
| Pretax Income | -95.63M |
| Net Income | -96.21M |
| EBITDA | -110.03M |
| EBIT | -110.12M |
| Earnings Per Share (EPS) | -$1.03 |
Full Income Statement Balance Sheet
The company has $1.02 billion in cash and $919,000 in debt, giving a net cash position of $1.02 billion or $8.82 per share.
| Cash & Cash Equivalents | 1.02B |
| Total Debt | 919,000 |
| Net Cash | 1.02B |
| Net Cash Per Share | $8.82 |
| Equity (Book Value) | 1.01B |
| Book Value Per Share | 8.96 |
| Working Capital | 1.01B |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -82.18M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 90,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -82.18M |
| FCF Per Share | -$0.71 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |